Schrodinger (SDGR)
(Delayed Data from NSDQ)
$21.37 USD
-0.42 (-1.93%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $21.36 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SDGR 21.37 -0.42(-1.93%)
Will SDGR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SDGR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SDGR
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
SDGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
Countdown to Schrodinger, Inc. (SDGR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Compared to Estimates, Schrodinger, Inc. (SDGR) Q3 Earnings: A Look at Key Metrics
Other News for SDGR
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
First Week of August 16th Options Trading For Schrodinger (SDGR)
Largest Clinical-Stage Biotech Drug Stocks Declined 6%